

# LIFE SAVING DRUGS PROGRAM (LSDP) EXPERT PANEL MEETING AGENDA

## 17 OCTOBER 2018 MEETING

The 17 October 2018 LSDP Expert Panel Agenda consists of the following:

- 1 **Report from Chair (verbal)**
- 2 **Correspondence**
- 3 **Other Business**
- 4 **LSDP Guidance Document**
- 5 **Review of LSDP medicines matters**
- 6 **New medicine applications**

Consumers will have the opportunity to provide comments on draft review Terms of Reference and new medicine applications. The **closing date** for consumer comments to be considered at the 17 October 2018 meeting is **5 October 2018**. Consumer comments can be made directly to [LSDPEP@health.gov.au](mailto:LSDPEP@health.gov.au).

As all new medicine applications to be considered by the LSDP Expert Panel will have already been considered by the PBAC for listing on the PBS, all consumer comments received throughout the corresponding PBAC process will be made available to the Panel. Stakeholders do not need to duplicate responses.

<b>Item under consideration</b>	<b>Drug Name and Sponsor</b> (Drug name, trade name, sponsor)	<b>Drug Type and Use</b> (What is the drug used to treat?)	<b>Purpose of item</b>
Review of LSDP medicines	Imiglucerase (Cerezyme <sup>®</sup> ) – Genzyme Velaglucerase (VPRIV <sup>®</sup> ) – Shire Taliglucerase (Elelyso <sup>®</sup> ) – Pfizer	Enzyme replacement therapy for treatment of Gaucher disease	To agree the draft Term of Reference for the review
Review of LSDP medicines	Agalsidase alfa (Replagal <sup>®</sup> ) Shire Agalsidase beta (Fabrazyme <sup>®</sup> ) Genzyme	Enzyme replacement therapy for treatment of Fabry disease	To agree the draft Term of Reference for the review
New medicine application	Cerliponase Alfa - BioMarin	Enzyme replacement therapy for treatment of Batten disease	To consider the new medicine application and develop advice for Commonwealth Chief Medical Officer on LSDP funding